Showing 1051-1060 of 20877 results for "".
- Early Inertial Training After ACL Reconstructionhttps://reachmd.com/news/early-inertial-training-after-acl-reconstruction/2487498/Key Takeaways Added inertial training was associated with greater restoration of morphological symmetry and interlimb symmetry under inertial loading. Isokinetic knee strength and dynamic balance were comparable between groups at 12 weeks. Onl
- mRNA Seasonal Influenza Vaccine Shows Superiority in Adultshttps://reachmd.com/news/mrna-seasonal-flu-vaccine-adults/2487477/Key Takeaways Investigators observed a relative vaccine efficacy of 26.6% with mRNA-1010, and the authors concluded superiority versus standard-dose licensed vaccines for the prespecified endpoint. Cases of RT-PCR–confirmed, protocol-defined influenza-
- Picankibart Phase III Trial Reports Week 16 Clearance and Week 52 Durabilityhttps://reachmd.com/news/picankibart-phase-iii-clearance-durability/2487475/Key Takeaways At week 16, both co-primary endpoints favored picankibart over placebo in Chinese adults with moderate to severe plaque psoriasis. All key secondary endpoints also improved, and efficacy was maintained through week 52 with both 100 mg and
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://reachmd.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- FDA Approves Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel for Midface Augmentationhttps://reachmd.com/news/fda-approves-obagi-saypha-chiq-injectable-hyaluronic-acid-gel-for-midface-augmentation/2487470/Waldencast plc announced that the US Food and Drug Administration (FDA) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (HA) gel, expanding the Obagi Medical injectable portfolio and strengthening the company’s position within the medical aesthetics market. According to the co
- High-Dose Intravenous Vitamin C Fails To Improve Burn Outcomeshttps://reachmd.com/news/high-dose-intravenous-vitamin-c-fails-to-improve-burn-outcomes/2487460/Key Takeaways High-dose intravenous vitamin C was not associated with improvement in the prespecified primary composite outcome, and 28-day mortality was higher in the vitamin C group. Time to discharge alive from hospital within 90 days was not improv
- Comparative Study Finds No Significant Melanoma Mortality Reduction From German Screening Initiativehttps://reachmd.com/news/comparative-study-finds-no-significant-melanoma-mortality-reduction-from-german-screening-initiative/2487471/A study of a German nationwide skin cancer screening (SCS) program showed reduced melanoma mortality compared with neighboring European countries that do not have population-based screening programs. Germany launched its nationwide SCS program in 2008, which included adults aged 35 years a
- Egg Allergy Prevalence Before and After Early Egg Introduction Guidelineshttps://reachmd.com/news/egg-allergy-prevalence-before-and-after-early-egg-introduction-guidelines/2487449/Key Takeaways The later cohort was associated with lower adjusted egg allergy prevalence than the earlier cohort. The observed reduction was larger among infants with early eczema. The comparison used two population-based Melbourne samples rec
- Intrawound Tobramycin Plus Vancomycin in Tibial Fracture Fixationhttps://reachmd.com/news/intrawound-tobramycin-plus-vancomycin-in-tibial-fracture-fixation/2487447/Key Takeaways Deep surgical site infection probabilities at 182 days were 7.4% with tobramycin plus vancomycin and 6.6% with vancomycin alone. The multicenter randomized trial at 39 US trauma centers compared intrawound tobramycin 1.2 g plus vancomycin
- Allergan Aesthetics Marks 8th Year of Partnership with Girls Inc. to Support Future Women in STEMhttps://reachmd.com/news/allergan-aesthetics-marks-8th-year-of-partnership-with-girls-inc-to-support-future-women-in-stem/2487445/Allergan Aesthetics is continuing its commitment to supporting the next generation of women in science, technology, engineering, and mathematics (STEM) through its longstanding partnership with Girls Inc. On June 8, the company marked its eighth year collaborating with the nonprofit organi